Research into the biology of renal cell carcinoma has led to the development of novel targeted therapies, including mTOR (mammalian target of rapamycin) inhibitors like Temsirolimus, as well as inhibitors of tyrosine kinase receptors from the division kinase domain family, such as Sunitinib and Sorafenib. Here, MTOR is linked to renal cell carcinoma.